Immunotherapy-boosted chemo shows striking early results against high-risk nasopharyngeal cancer
A prospective phase II pilot study from non-endemic Sichuan reports 95.2 percent response rates and 80 percent event-free survival at ...
A prospective phase II pilot study from non-endemic Sichuan reports 95.2 percent response rates and 80 percent event-free survival at ...
When a patient with cervical cancer finishes radical surgery and then faces weeks of postoperative adjuvant concurrent chemoradiotherapy, the treatment ...
In the relentless pursuit of more effective cancer therapies, a pioneering clinical trial has emerged, casting new light on the ...
© 2026 Scienmag - Science Magazine
© 2026 Scienmag - Science Magazine